Accelerated communication assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites

Drug Metabolism and Disposition

Volumn 38, Issue 10, 2010, Pages 1900-1905

  Wang, Wendy WeiWei ^a   Khetani, Salman R ^b   Krzyzewski, Stacy ^b   Duignan, David B ^a   Obach, R Scott ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Hepregen Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 TRIFLUOROMETHOXYSALICYLIC ACID; 6BETA HYDROXYEPLERENONE; 6BETA,21 DIHYDROXEPLERENONE; 7 TRIFLUOROMETHYLQUINALDIC ACID; AXITINIB GLUCURONIDE; AXITINIB SULFOXIDE; BISTRIFLUOROMETHYL BENZOIC ACID; CELECOXIB GLUCURONIDE; DEPYRIDINYL DELAVIRDINE; DESTHIOPHENE TOFIMULAST; DIHYDROXYTOFIMULAST; DRUG METABOLITE; GEMCABENE GLUCURONIDE; HYDROXYAVASIMIBE; HYDROXYAXITINIB; HYDROXYCAPRAVIRINE SULFOXIDE; HYDROXYMETHYL MARAVIROC; HYDROXYPAGOCLONE; HYDROXYSUNEPITRON; HYDROXYVALDECOXIB GLUCURONIDE; HYDROXYZONIPORIDE; LASOFOXIFENE GLUCURONIDE; N DEALKYLDELAVIRDINE; N DESMETHYL O DEBENZYL HYDROXYCAPROMORELIN; TRAXOPRODIL METHOXY GLUCURONIDE; TRAXOPRODIL METHOXY SULFATE; TROVAFLOXACIN GLUCURONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALDECOXIB N GLUCURONIDE; ZIPRASIDONE SULFOXIDE; DRUG;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG EXCRETION; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIVER CELL; LIVER MICROSOME; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL; BIOLOGICAL MODEL; CELL CULTURE; CHEMISTRY; COCULTURE; CRYOPRESERVATION; DRUG DETOXIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; METHODOLOGY; PREDICTIVE VALUE; TANDEM MASS SPECTROMETRY;

CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COCULTURE TECHNIQUES; CRYOPRESERVATION; HEPATOCYTES; HUMANS; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; TANDEM MASS SPECTROMETRY;

EID: 77957118925     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.034876     Document Type: Article

References (11)

1. Anderson S, Luffer-Atlas D, and Knadler MP (2009) Predicting circulating human metabolites: how good are we? Chem Res Toxicol 22:243-256.
2. Atrakchi AH (2009) Interpretation and considerations on the safety evaluation of human drug metabolites. Chem Res Toxicol 22:1217-1220.
3. Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, Bu HZ, et al. (2009) Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357-368.
4. Guillouzo A and Guguen-Guillouzo C (2008) Evolving concepts in liver tissue modeling and implications for in vitro toxicology. Expert Opin. Drug Metab Toxicol 4:1279-1294.
5. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
6. Khetani SR and Bhatia SN (2008) Microscale culture of human liver cells for drug development. Nat Biotechnol 26:120-126.
7. Prakash C, Kamel A, Gummerus J, and Wilner K (1997) Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos 25:863-872. (Pubitemid 27318605)
8. Robison TW and Jacobs A (2009) Metabolites in safety testing. Bioanalysis 1:1193-1200.
9. 14C]linezolid to healthy human subjects. Drug Metab Dispos 29:1136-1145.
10. Smith DA and Obach RS (2009) Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22:267-279.
11. Wynalda MA, Hauer MJ, and Wienkers LC (2000) Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metab Dispos 28:1014-1017.